Pfizer raises full-year profit and revenue outlook
Pfizer cited strong demand for cancer drug Padcev and blood thinner Eliquis.
Related stories
Array Technologies to Merge With Shoals in an All-Stock Deal
Array Technologies and Shoals will combine in an all-stock transaction.
M impact | EQUITY | Nov 04, 2026, 02:21 PM UTC
Enviri Exits Deutsche Bahn Contract, Expects $19 Million Gain
Enviri released Harsco Rail from its Deutsche Bahn contract after repaying approximately $73 million in advances. The company expects a net gain of approximately $19 million with t
M impact | EQUITY | Nov 04, 2026, 02:09 PM UTC
Alphabet Backs TeraWulf Credit for Anthropic Data Center Project
TeraWulf receives credit backing from Alphabet for its data center project for Anthropic.
M impact | EQUITY | Nov 04, 2026, 02:08 PM UTC
Vivakor Highlights Potential Annual Service Revenue Above $2 Million
Direct Midstream’s conditional agreement to operate 52 New Mexico wells could generate more than $2 million in annual service revenue at targeted operating levels, subject to final
M impact | EQUITY | Nov 04, 2026, 02:08 PM UTC
TeraWulf Gets Google Credit Backing for Anthropic Data Center Project
M impact | EQUITY | Nov 04, 2026, 02:08 PM UTC
TeraWulf Gets Google Credit Backstop for Anthropic Data-Center Project
M impact | EQUITY | Nov 04, 2026, 02:08 PM UTC